Literature DB >> 24275478

Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice.

Weibin Zhou1, Albanus O Moguche2, David Chiu3, Kaja Murali-Krishna2, François Baneyx4.   

Abstract

Distributed and on-demand vaccine production could be game-changing for infectious disease treatment in the developing world by providing new therapeutic opportunities and breaking the refrigeration "cold chain". Here, we show that a fusion protein between a calcium phosphate binding domain and the model antigen ovalbumin can mineralize a biocompatible adjuvant in a single step. The resulting 50 nm calcium phosphate core-immunogen shell particles are comparable to soluble protein in inducing ovalbumin-specific antibody response and class switch recombination in mice. However, single dose vaccination with nanoparticles leads to higher expansion of ovalbumin-specific CD8(+) T cells upon challenge with an influenza virus bearing the ovalbumin-derived SIINFEKL peptide, and these cells produce high levels of IFN-γ. Furthermore, mice exhibit a robust antigen-specific CD8(+) T cell recall response when challenged with virus 8 months post-immunization. These results underscore the promise of immunogen-controlled adjuvant mineralization for just-in-time manufacturing of effective T cell vaccines. FROM THE CLINICAL EDITOR: This paper reports that a fusion protein between a calcium phosphate binding domain and the model antigen ovalbumin can mineralize into a biocompatible adjuvant in a single step, enabling distributed and on-demand vaccine production and eliminating the need for refrigeration of vaccines. The findings highlight the possibility of immunogen-controlled adjuvant mineralization for just-in-time manufacturing of effective T cell vaccines.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biomineralization; Nanocarrier; Nanovaccine; Solid binding peptide

Mesh:

Substances:

Year:  2013        PMID: 24275478      PMCID: PMC3966940          DOI: 10.1016/j.nano.2013.11.007

Source DB:  PubMed          Journal:  Nanomedicine        ISSN: 1549-9634            Impact factor:   5.307


  40 in total

Review 1.  Towards tailored vaccine delivery: needs, challenges and perspectives.

Authors:  Jean-Pierre Amorij; Gideon F A Kersten; Vinay Saluja; Wouter F Tonnis; Wouter L J Hinrichs; Bram Slütter; Suzanne M Bal; Joke A Bouwstra; Anke Huckriede; Wim Jiskoot
Journal:  J Control Release       Date:  2012-01-05       Impact factor: 9.776

2.  Nanotechnology Meets Biology: Peptide-based Methods for the Fabrication of Functional Materials.

Authors:  Beverly D Briggs; Marc R Knecht
Journal:  J Phys Chem Lett       Date:  2012-01-19       Impact factor: 6.475

3.  Aqueous, protein-driven synthesis of transition metal-doped ZnS immuno-quantum dots.

Authors:  Weibin Zhou; François Baneyx
Journal:  ACS Nano       Date:  2011-09-28       Impact factor: 15.881

4.  Biomineralization and size control of stable calcium phosphate core-protein shell nanoparticles: potential for vaccine applications.

Authors:  David Chiu; Weibin Zhou; Sathana Kitayaporn; Daniel T Schwartz; Kaja Murali-Krishna; Terrance J Kavanagh; François Baneyx
Journal:  Bioconjug Chem       Date:  2012-02-10       Impact factor: 4.774

5.  The role of antigen in the localization of naive, acutely activated, and memory CD8(+) T cells to the lung during influenza pneumonia.

Authors:  D J Topham; M R Castrucci; F S Wingo; G T Belz; P C Doherty
Journal:  J Immunol       Date:  2001-12-15       Impact factor: 5.422

6.  Calcium phosphate nanoparticles induce mucosal immunity and protection against herpes simplex virus type 2.

Authors:  Qing He; Alaina Mitchell; Tulin Morcol; Steve J D Bell
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 7.  Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists.

Authors:  Jörg Vollmer; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2009-01-13       Impact factor: 15.470

8.  Virus-specific CD8+ T cells in primary and secondary influenza pneumonia.

Authors:  K J Flynn; G T Belz; J D Altman; R Ahmed; D L Woodland; P C Doherty
Journal:  Immunity       Date:  1998-06       Impact factor: 31.745

9.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

Authors:  Sai T Reddy; Annemie Rehor; Hugo G Schmoekel; Jeffrey A Hubbell; Melody A Swartz
Journal:  J Control Release       Date:  2006-03-10       Impact factor: 9.776

10.  CD8+ T cells accumulate in the lungs of Mycobacterium tuberculosis-infected Kb-/-Db-/- mice, but provide minimal protection.

Authors:  Kevin B Urdahl; Denny Liggitt; Michael J Bevan
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

View more
  8 in total

1.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

2.  Enhancement of MHC-I antigen presentation via architectural control of pH-responsive, endosomolytic polymer nanoparticles.

Authors:  John T Wilson; Almar Postma; Salka Keller; Anthony J Convertine; Graeme Moad; Ezio Rizzardo; Laurence Meagher; John Chiefari; Patrick S Stayton
Journal:  AAPS J       Date:  2014-12-12       Impact factor: 4.009

Review 3.  Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections.

Authors:  Tejabhiram Yadavalli; Deepak Shukla
Journal:  Nanomedicine       Date:  2016-08-26       Impact factor: 5.307

Review 4.  Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation.

Authors:  Robert K DeLong; Chandler B Curtis
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-06-16

Review 5.  Functional nanomaterials can optimize the efficacy of vaccines.

Authors:  Ye Liu; Yingying Xu; Yue Tian; Chunying Chen; Chen Wang; Xingyu Jiang
Journal:  Small       Date:  2014-09-19       Impact factor: 13.281

Review 6.  Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications.

Authors:  Christopher D Spicer; Coline Jumeaux; Bakul Gupta; Molly M Stevens
Journal:  Chem Soc Rev       Date:  2018-05-21       Impact factor: 54.564

7.  Calcium Phosphate as a Key Material for Socially Responsible Tissue Engineering.

Authors:  Vuk Uskoković; Victoria M Wu
Journal:  Materials (Basel)       Date:  2016-06-01       Impact factor: 3.623

8.  The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: The immunological consequences of the biodistribution profile.

Authors:  Signe Tandrup Schmidt; Swapnil Khadke; Karen Smith Korsholm; Yvonne Perrie; Thomas Rades; Peter Andersen; Camilla Foged; Dennis Christensen
Journal:  J Control Release       Date:  2016-08-26       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.